Legal Representation
Attorney
John Stattler
USPTO Deadlines
Application History
23 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Mar 14, 2016 | MAB6 | O | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED | Loading... |
| Mar 14, 2016 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED | Loading... |
| Aug 11, 2015 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Jun 16, 2015 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Jun 16, 2015 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| May 27, 2015 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| May 9, 2015 | PREV | O | LAW OFFICE PUBLICATION REVIEW COMPLETED | Loading... |
| May 9, 2015 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Apr 16, 2015 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Apr 16, 2015 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
| Apr 16, 2015 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... |
| Apr 16, 2015 | GNEA | O | EXAMINERS AMENDMENT E-MAILED | Loading... |
| Apr 16, 2015 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... |
| Mar 24, 2015 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Mar 23, 2015 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Mar 23, 2015 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Mar 23, 2015 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| Sep 23, 2014 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Sep 23, 2014 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Sep 23, 2014 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Sep 16, 2014 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Jun 17, 2014 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Jun 7, 2014 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 042
Research and development of health care products, namely, research and development of diagnostics and drugs for central nervous system indications, including neurodegenerative diseases
First Use Anywhere:
0
First Use in Commerce:
0
Classification
International Classes
042